Roche, Trimeris Seek FDA Approval to Use Needle-Free Injection Device to Administer Antiretroviral Fuzeon
July 19, 2005
Pharmaceutical companies Roche and Trimeris on Monday announced they have filed for FDA approval to use a needle-free injection device to administer the antiretroviral drug Fuzeon, the AP/Forbes.com reports. The Biojector 2000 injection system, which is manufactured by Bioject Medical Technologies, uses power from a CO2 cartridge to spread liquid medication through the skin. The device has been available since 1996 and is used to administer subcutaneous and intramuscular medications. Fuzeon, which is a fusion inhibitor, currently is approved for use with a needle and syringe. The companies said they expect FDA to make a decision on the application later this year. Roche and Trimeris also announced plans to test patient acceptance of the device in a clinical trial, called the Fuzeon Wand study (AP/Forbes.com, 7/18).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.